PM534 IV treatment for advanced solid tumors
Part of Cancer clinical trials.
This early-phase study tests PM534 given through an IV to see if it is safe and how well it works in people with advanced solid tumors. It may help by finding a new treatment option, but eligibility is strict to protect participants from side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are able to sign consent before any study procedures
- Your health/activity level is ECOG 0 to 1 (fully active or limited but up and about)
- You have advanced solid tumors confirmed by pathology, and you’ve had 0–3 prior chemotherapy treatments
- You have cancer that doctors can measure or track on scans (measurable or non-measurable disease)
- Blood tests before the first infusion must be strong enough (enough white blood cells, platelets, and hemoglobin; liver and kidney numbers within limits; also potassium and magnesium are adequate)
- You can wait long enough after prior treatments (at least 3 weeks from chemo, 4 weeks from monoclonal antibody therapy, and others as specified)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests PM54, a study drug, in people with advanced (cancer that has spread) solid tumors when standard treatments are no longer working. It focuses on safety and early signs of how well the treatment may work in specific cancer types.
This study tests a new drug called PM54 combined with pembrolizumab (an immunotherapy) in people with advanced cancers that have gotten worse despite prior treatment. The goal is to see if this combination can slow or stop cancer growth.
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
This Phase 1/2 study tests PM8002 in people with advanced solid cancers to see if it can work and is safe. It may help if your cancer has measurable disease and you have not fully recovered from side effects of prior treatment.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
Hear when a new Patients With Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.